ImmunoGen, Takeda Partner to Develop Ovarian Cancer Drug in Japan
Takeda will develop and commercialize ImmunoGen's antibody-drug conjugate Elahere in Japan as a treatment for FRα-positive ovarian cancer.
Stay updated with breaking news from Roche Ventana. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Takeda will develop and commercialize ImmunoGen's antibody-drug conjugate Elahere in Japan as a treatment for FRα-positive ovarian cancer.
Seed round co-led by Wellington Partners and Forbion, with non-dilutive funding from BMBF GO-Bio enables maturation of platform and pipeline towards first clinical evaluation Seamless Therapeutics
Arlington, VA (PRWEB) November 10, 2022 -- The market for the testing of tissues and cells, histology and cytology in vitro diagnostics reached $4.9 billion
Oversubscribed financing round with top-tier life science investors, led by Wellington Partners Spin-off from Charité – Universitätsmedizin Berlin developing
Oversubscribed financing round with top-tier life science investors, led by Wellington PartnersSpin-off from Charité – Universitätsmedizin Berlin...